List of Excipients in Branded Drug TOLMETIN SODIUM

Generic Drugs Containing TOLMETIN SODIUM

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	tolmetin sodium	0378-0313	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	tolmetin sodium	0378-0313	CROSPOVIDONE
Mylan Pharmaceuticals Inc	tolmetin sodium	0378-0313	FERRIC OXIDE YELLOW
Mylan Pharmaceuticals Inc	tolmetin sodium	0378-0313	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in TOLMETIN SODIUM?

# Of NDCs	Excipient
6	CELLULOSE, MICROCRYSTALLINE
4	CROSCARMELLOSE SODIUM
6	CROSPOVIDONE
1	D&C YELLOW NO. 10

Tolmetin Sodium Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Tolmetin sodium is an old, immediate-release NSAID with a largely expired intellectual-property position and limited current commercial visibility in the United States. Its sodium-salt form is suitable for conventional oral tablets and capsules because it improves aqueous solubility. The strongest commercial opportunities are low-cost generic reintroduction, differentiated oral dosage forms, pediatric liquid development, and controlled-release or gastroprotective products pursued through a new regulatory pathway.

What is the regulatory and commercial status of tolmetin sodium?

Tolmetin sodium is the sodium salt of tolmetin, a pyrrole acetic acid NSAID. The original product, Tolectin, was approved in the United States for rheumatoid arthritis and osteoarthritis. Historical strengths included 200 mg, 400 mg, and 600 mg tablets, with 200 mg capsules also marketed in some product configurations.

Attribute	Tolmetin sodium
Pharmacologic class	NSAID
Chemical class	Pyrrole acetic acid derivative
Molecular formula	C13H11N2NaO3
Approximate molecular weight	258.23 g/mol
Historical U.S. brand	Tolectin
Historical dosage forms	Immediate-release tablets and capsules
Historical strengths	200 mg, 400 mg, 600 mg
Primary indications	Rheumatoid arthritis and osteoarthritis
Administration	Oral
Biologic status	Not applicable
Generic pathway	Abbreviated New Drug Application, if an approved reference product is available
Commercial position	Mature, low-volume, generic opportunity

Tolmetin sodium is not a biologic and has no biosimilar exposure. Competition would come from generic manufacturers, reformulation companies, and potentially 505(b)(2) applicants rather than biosimilar developers.

The commercial opportunity is constrained by the availability of many established NSAIDs, including ibuprofen, naproxen, diclofenac, meloxicam, celecoxib, and indomethacin. A tolmetin sodium product would need a cost, tolerability, dosing, supply, or delivery advantage to gain meaningful market share.

What patents protect tolmetin sodium?

The original composition-of-matter and product patents for tolmetin sodium are expected to be expired because the product was first approved in the 1970s. Any historical patents covering tolmetin, tolmetin sodium, or the Tolectin product would be well beyond their ordinary 20-year patent term.

Patent category	Current strategic assessment
Tolmetin active ingredient	Historical patents expired
Tolmetin sodium salt	Historical patents expired or commercially ineffective
Immediate-release tablets	Historical product protection expired
Capsule formulations	Historical product protection expired
Method of treatment for arthritis	Historical patents expired
Manufacturing process	Legacy processes may be expired; process know-how can still matter
New controlled-release formulation	Potentially patentable if technically and clinically distinct
Pediatric liquid formulation	Potentially patentable if formulation and use claims are novel
Topical or local-delivery formulation	Potentially patentable, but requires new development evidence
Combination product	Potentially patentable if the combination and clinical use are novel

The remaining competitive protection is more likely to arise from manufacturing efficiency, validated specifications, regulatory data, supply reliability, and formulation know-how than from legacy tolmetin patents.

When does tolmetin sodium lose exclusivity?

Tolmetin sodium lost meaningful market exclusivity decades ago. The original U.S. small-molecule exclusivity period has expired, and any ordinary patent term tied to the first product approval would also have expired.

A new applicant would not obtain market exclusivity merely by manufacturing an equivalent immediate-release tablet. A differentiated product could qualify for limited exclusivity under the Federal Food, Drug, and Cosmetic Act if it relies on a qualifying new clinical investigation or a new formulation pathway.

Potential exclusivity categories include:

Development route	Possible exclusivity
Standard ANDA for an equivalent product	Generally no new clinical exclusivity
505(b)(2) with new clinical investigations	Possible three-year exclusivity for the approved change
New chemical entity route	Not applicable to tolmetin sodium
Orphan-drug route	Unlikely for conventional arthritis indications
Pediatric studies	Possible pediatric exclusivity if statutory requirements are met
New indication	Potentially three-year exclusivity if supported by qualifying studies

The commercial value of a new exclusivity period would depend on whether the product creates a clinically meaningful distinction from inexpensive conventional NSAIDs.

What is the Orange Book status of tolmetin sodium?

The FDA Orange Book is the governing source for current reference-listed-drug status, therapeutic-equivalence evaluations, and patent or exclusivity listings. Historical Tolectin products have appeared in FDA approval records, but the commercial status of individual strengths and reference products must be assessed against the current Orange Book and Drugs@FDA databases.

The key regulatory issue is whether an active reference-listed drug remains available for an ANDA pathway. If no active reference-listed drug is available, a sponsor may need to evaluate:

1. A petitioned ANDA strategy.
2. A 505(b)(2) application.
3. A suitability petition, if the proposed product differs in a permitted way.
4. A new NDA supported by clinical and bioavailability data.

A revived product should not assume that an old brand label automatically provides a straightforward ANDA reference. FDA approval history, current marketing status, reference-product designation, product-specific guidance, and discontinued-drug records must be reviewed before formulation investment.

What excipients are suitable for tolmetin sodium tablets?

Tolmetin sodium is a strong candidate for a conventional immediate-release matrix. The sodium salt supports dissolution, reducing the need for complex solubilization technology. The main formulation risks are blend uniformity, tabletability at high dose, moisture control, disintegration, and NSAID-related gastrointestinal tolerability.

Immediate-release tablet platform

A practical formulation platform can use:

Functional role	Candidate excipients	Development purpose
Diluent	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate	Adjust tablet weight and improve compression
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improve granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promote rapid breakup
Glidant	Colloidal silicon dioxide	Improve powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduce sticking and ejection force
Film former	Hypromellose, polyvinyl alcohol	Improve appearance, handling, and swallowability
Plasticizer	Polyethylene glycol or triethyl citrate	Support film flexibility
Opacifier	Titanium dioxide where permitted and appropriate	Improve opacity and product appearance
Colorant	Iron oxides or approved aluminum lakes	Product identification

For a 600 mg strength, direct compression may create a large tablet and increase the risk of capping or poor swallowability. A wet-granulation or dry-granulation process may provide better content uniformity and mechanical strength, although wet processing requires tighter moisture and drying controls.

A dry-granulation process is attractive where the active ingredient or selected excipients show moisture sensitivity. Roller compaction can reduce thermal and aqueous exposure, but it may increase granule fines and alter dissolution. The formulation should be designed around dissolution performance rather than compression force alone.

Capsule platform

Hard capsules can simplify manufacturing for a 200 mg presentation. Capsules may be commercially useful where tablet size, dose flexibility, or patient swallowability is a concern. The formulation must control powder flow and segregation, particularly if the active drug represents a large fraction of fill weight.

Capsule shell selection should consider:

• Gelatin versus hypromellose shells.
• Moisture transfer.
• Shell brittleness under low humidity.
• Compatibility with the sodium salt.
• Machine-fill performance.
• Regional excipient restrictions.

Capsules can support lower tooling costs for a first commercial launch, while tablets may offer lower unit cost at scale.

What formulation patents could protect a new tolmetin sodium product?

The legacy immediate-release product is unlikely to support meaningful new patent protection. A sponsor would need to claim a genuine technical or clinical distinction.

Potential formulation patent targets include:

1. Controlled-release multiparticulates that reduce dosing frequency.
2. Gastroretentive systems that alter exposure.
3. Enteric-coated dosage forms designed to delay release.
4. Orally disintegrating tablets with acceptable taste and low tablet mass.
5. Pediatric oral suspensions with improved physical and chemical stability.
6. Topical gels, creams, or transdermal systems.
7. Fixed-dose combinations with gastroprotective or analgesic agents.
8. Abuse-resistant or dose-limiting delivery systems, although the abuse rationale is weak for tolmetin.
9. Low-sodium formulations for patients requiring sodium restriction.
10. Amorphous or co-processed systems with improved dissolution or manufacturability.

A patent on excipient selection alone would be vulnerable unless the formulation produces an unexpected technical result, such as superior stability, dissolution, bioavailability, taste, or reduced variability.

What excipient strategy is best for a pediatric tolmetin sodium liquid?

A pediatric liquid could provide the clearest dosage-form differentiation, but it would require careful stability and palatability work. Tolmetin sodium is more suitable for an aqueous product than the free acid because the salt form improves water compatibility. The formulation still requires pH control, microbial protection, taste masking, and container compatibility.

A liquid strategy could include:

Formulation element	Commercial objective
Buffered aqueous vehicle	Maintain pH and chemical stability
Sweetener	Improve acceptability
Flavor system	Reduce NSAID bitterness
Suspending or viscosity agent	Maintain dose uniformity if a suspension is used
Preservative system	Control microbial growth in multidose packaging
Chelating agent	Limit metal-catalyzed degradation where justified
Antifoam or wetting aid	Improve manufacturing and dose reproducibility
Child-resistant closure	Meet packaging requirements

An oral suspension may be preferable to a clear solution if taste, concentration, or chemical stability is better in a dispersed system. A solution offers easier dose uniformity but can expose the active ingredient continuously to the aqueous environment. Either approach would require in-use stability data, dosing-device validation, extractables and leachables testing, and palatability assessment.

A pediatric indication or pediatric dosage form could create a better commercial position than another adult tablet, but it would not eliminate the need to demonstrate appropriate dosing and safety.

Can enteric-coated or controlled-release tolmetin sodium products create value?

Yes, but the regulatory and technical burden is materially higher than for an immediate-release generic.

An enteric-coated product could be positioned around delayed gastric release. That does not automatically demonstrate improved gastrointestinal safety. Systemic NSAID toxicity, including gastrointestinal bleeding, can remain clinically relevant after delayed release. A sponsor should not rely on enteric coating as a safety claim without clinical evidence.

Controlled release could support once-daily or twice-daily dosing. The primary development risks are:

• Dose dumping.
• Food effects.
• Variable gastrointestinal transit.
• Incomplete release.
• Altered peak and trough exposure.
• Failure to demonstrate bioequivalence.
• Need for clinical bridging under a 505(b)(2) application.

A multiparticulate system may offer better release control than a single matrix tablet. It also creates higher manufacturing complexity and more opportunities for patentable process or coating claims.

What manufacturing and IP barriers affect tolmetin sodium?

Tolmetin sodium has limited active-ingredient patent barriers, but manufacturing execution remains commercially relevant.

Key barriers include:

• Reliable API supply at pharmaceutical grade.
• Control of sodium content and assay.
• Residual solvent and impurity specifications.
• Control of polymorphic or solid-state variation.
• Hygroscopicity and moisture uptake.
• Powder-flow limitations.
• High-dose tablet size.
• Blend segregation.
• Dissolution reproducibility.
• Cleaning validation for potent, low-dose or dusty materials.
• Stability in high-humidity markets.
• Global excipient compliance.

Process patents may be available for a genuinely new route, impurity-control method, crystallization method, or particle-engineering process. These rights would protect manufacturing know-how rather than the historical active ingredient.

A dual-source API strategy would reduce supply risk but may require bridging data if particle size, crystal form, impurity profile, or dissolution performance changes.

Are there Paragraph IV challenges for tolmetin sodium?

Paragraph IV litigation is unlikely to be a major current issue for an old tolmetin sodium immediate-release product. Any historical Orange Book patents associated with Tolectin would be expected to have expired. A modern ANDA applicant would still need to certify against any currently listed patents for the relevant reference product.

Potential litigation could arise from:

• A newly listed formulation patent.
• A 505(b)(2) product with a patented delivery system.
• Patent claims covering a new indication.
• Process or polymorph claims asserted outside the ordinary Orange Book framework.
• Trade-secret disputes involving API manufacture.

The practical generic-entry risk is therefore regulatory and commercial rather than patent-driven. A sponsor should expect price competition if multiple manufacturers enter.

Which companies could challenge or compete with tolmetin sodium?

The competitive field includes generic NSAID manufacturers and contract development and manufacturing organizations with oral-solid-dose capability. Relevant competitors would include companies active in generic ibuprofen, naproxen, diclofenac, indomethacin, and other anti-inflammatory products.

Potential competitor categories are:

Competitor type	Likely strategy
Large generic companies	Low-cost tablets or capsules
Regional generic manufacturers	Local registration and tender supply
Specialty formulation companies	Pediatric liquid, ODT, or modified release
CDMOs	Development, scale-up, and private-label supply
Branded reformulation companies	505(b)(2) differentiated product
API manufacturers	Vertical integration and supply contracts

Tolmetin sodium would compete against drugs with stronger physician familiarity and larger established markets. A commercial launch would need targeted positioning, such as formulary supply, dose flexibility, pediatric use, or a differentiated delivery format.

How does tolmetin sodium compare with competing NSAIDs?

Product	Typical commercial strength	Differentiation relative to tolmetin sodium
Ibuprofen	Very broad, including OTC	Lower-cost and highly familiar
Naproxen	Broad prescription and OTC use	Longer duration and strong market presence
Diclofenac	Large global market	Multiple oral and topical formulations
Meloxicam	Prescription arthritis market	Once-daily dosing
Celecoxib	Prescription COX-2 market	COX-2 positioning and branded history
Indomethacin	Specialty anti-inflammatory use	Strong niche positioning
Tolmetin sodium	Legacy prescription NSAID	Limited current commercial differentiation

Tolmetin sodium may have a place in a focused generic portfolio, but it is unlikely to support premium pricing as an undifferentiated tablet. A company with an existing rheumatology, hospital, or government-tender portfolio may obtain more value than a new entrant without distribution infrastructure.

What licensing deals and settlement agreements affect tolmetin sodium?

No major active licensing or settlement structure is generally associated with legacy tolmetin sodium products. The original brand-related rights are not the central commercial constraint.

New transactions could involve:

• API supply and volume commitments.
• Regional commercialization rights.
• Development of pediatric or modified-release products.
• Co-development under a 505(b)(2) pathway.
• Private-label manufacturing.
• Licensing of taste-masking or multiparticulate technology.

The most defensible transaction structure would link milestones to FDA acceptance, bioequivalence, approval, and commercial supply rather than rely on legacy brand value.

What generic launch scenarios exist for tolmetin sodium?

Scenario 1: Immediate-release generic tablets

This is the lowest-risk technical route. It offers the shortest development timeline and lowest clinical burden if an acceptable reference product is available. The main risk is weak market size and rapid price erosion.

Scenario 2: 200 mg capsules

Capsules can reduce development complexity and improve patient acceptability. The opportunity is strongest where a tablet reference is unavailable but a capsule product can support a viable regulatory strategy.

Scenario 3: Pediatric oral liquid

This creates a more defensible commercial niche. It requires greater investment in taste masking, stability, packaging, and clinical dosing.

Scenario 4: Modified-release product

A once-daily formulation could create differentiation and possible three-year exclusivity through a 505(b)(2) route. It carries materially higher development and bioequivalence risk.

Scenario 5: Topical formulation

A topical gel or cream could target localized musculoskeletal pain. It would likely require new pharmacokinetic, local-tolerance, and efficacy work. The product would compete with established topical diclofenac and other topical NSAIDs.

What geographic opportunities exist?

The United States may offer a regulatory pathway but limited demand for a legacy NSAID. Markets with established generic procurement and lower development costs may be more attractive, including selected Latin American, Middle Eastern, Asian, and African jurisdictions.

Geographic priorities should reflect:

• Existing tolmetin sodium registration.
• Local reference-product requirements.
• Acceptance of U.S. or European bioequivalence data.
• NSAID prescription status.
• Tender purchasing.
• API import controls.
• Excipient restrictions.
• Local pharmacovigilance requirements.
• Reimbursement and substitution rules.

A global launch would likely require separate evaluation of tablet strengths, labeling, preservative systems, colorants, and approved excipient inventories.

How strong is the tolmetin sodium patent estate?

The patent estate is weak for conventional immediate-release products and potentially moderate for genuinely new delivery systems.

Estate component	Relative strength
Active ingredient	Very low
Sodium salt	Very low
Conventional tablet	Very low
Conventional capsule	Very low
New pediatric liquid	Moderate if claims are technically supported
Modified release	Moderate to potentially strong
Topical delivery	Moderate, subject to clinical differentiation
Manufacturing process	Moderate if novel and difficult to design around
Trade secrets and know-how	Commercially relevant but not publicly enforceable like patents

Patent value would depend on claim scope, prosecution history, freedom to operate, and the ability to demonstrate unexpected performance. A formulation patent that merely substitutes one standard disintegrant for another would have limited defensive value.

Key Takeaways

• Tolmetin sodium is an old, non-biologic NSAID with expired legacy exclusivity.
• The immediate-release tablet and capsule opportunity is primarily a low-cost generic play.
• The sodium salt supports conventional oral formulation because of improved water compatibility.
• Microcrystalline cellulose, povidone, croscarmellose sodium or crospovidone, colloidal silicon dioxide, and magnesium stearate are practical starting points for oral-solid-dose development.
• High-dose tablets may require granulation to manage tablet size, strength, and dissolution.
• Pediatric liquids, orally disintegrating tablets, modified-release systems, and topical products offer more defensible differentiation.
• Enteric coating should not be marketed as a gastrointestinal-safety solution without clinical evidence.
• Paragraph IV litigation and biosimilar risk are low relative to regulatory, supply, and commercial risks.
• The current Orange Book and Drugs@FDA records should control reference-product and patent-certification decisions.
• The strongest commercial strategy is a targeted generic or differentiated dosage form supported by efficient API sourcing and a focused market.

Frequently Asked Questions

Is tolmetin sodium still commercially available in the United States?

Tolmetin sodium has historical U.S. approval and brand-market presence, but its current commercial availability should be determined from FDA approval and marketing-status records rather than historical Tolectin labeling.

Can tolmetin sodium be developed as an over-the-counter product?

An OTC product would require an appropriate regulatory basis and labeling supported by FDA requirements. Historical prescription approval does not establish OTC eligibility.

Is tolmetin sodium suitable for an orally disintegrating tablet?

Yes. Its oral solid dose can be adapted to an orally disintegrating tablet, but taste masking, tablet friability, dose mass, and rapid dissolution would be central development issues.

What is the most attractive new formulation for tolmetin sodium?

A pediatric oral liquid or a carefully engineered modified-release product offers more differentiation than another conventional immediate-release tablet. The liquid has lower delivery-system complexity, while modified release may offer stronger exclusivity potential.

Does tolmetin sodium have a biosimilar pathway?

No. Tolmetin sodium is a small-molecule drug. A follow-on product would use an ANDA, 505(b)(2), or NDA pathway rather than the biosimilar framework.

References

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2019). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. National Library of Medicine. (n.d.). Tolmetin sodium drug information and labeling records. DailyMed. https://dailymed.nlm.nih.gov/

5. U.S. Food and Drug Administration. (2022). Abbreviated new drug application submissions: Refuse-to-receive standards. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). U.S. Department of Health and Human Services.